US20050202010A1 - Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor - Google Patents

Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor Download PDF

Info

Publication number
US20050202010A1
US20050202010A1 US10/927,494 US92749404A US2005202010A1 US 20050202010 A1 US20050202010 A1 US 20050202010A1 US 92749404 A US92749404 A US 92749404A US 2005202010 A1 US2005202010 A1 US 2005202010A1
Authority
US
United States
Prior art keywords
mif
subject
treating
preventing
need
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/927,494
Other languages
English (en)
Inventor
Brett Giroir
Monte Willis
Vidal De La Cruz
Thais Sielecki-Dzurdz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokine Pharmasciences Inc
University of Texas System
Original Assignee
Cytokine Pharmasciences Inc
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokine Pharmasciences Inc, University of Texas System filed Critical Cytokine Pharmasciences Inc
Priority to US10/927,494 priority Critical patent/US20050202010A1/en
Priority to EP16170803.7A priority patent/EP3078386A3/en
Priority to CA2537928A priority patent/CA2537928C/en
Priority to CN2004800247776A priority patent/CN1972713B/zh
Priority to EP04782427.1A priority patent/EP1658037B1/en
Priority to JP2006524893A priority patent/JP4891769B2/ja
Priority to HUE04782427A priority patent/HUE029888T2/en
Priority to PL04782427T priority patent/PL1658037T3/pl
Priority to PCT/US2004/027945 priority patent/WO2005020919A2/en
Priority to PT47824271T priority patent/PT1658037T/pt
Priority to ES04782427.1T priority patent/ES2599032T3/es
Priority to BRPI0413404-4A priority patent/BRPI0413404A/pt
Priority to DK04782427.1T priority patent/DK1658037T3/en
Priority to AU2004268017A priority patent/AU2004268017B2/en
Priority to MXPA06001828A priority patent/MXPA06001828A/es
Priority to CN201110370579.7A priority patent/CN102499984B/zh
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, CYTOKINE PHARMASCIENCES, INC. reassignment BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SIELECKI-DZURDZ, THAIS M., DE LA CRUZ JR., VIDAL F, GIROIR, BRETT P., WILLIS, MONTE S.
Publication of US20050202010A1 publication Critical patent/US20050202010A1/en
Priority to MX2011013436A priority patent/MX340217B/es
Priority to US11/932,909 priority patent/US8747843B2/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF TEXAS SW MEDICAL CENTER AT DALLAS
Priority to JP2010039451A priority patent/JP5905659B2/ja
Priority to JP2011133728A priority patent/JP2011251966A/ja
Priority to US14/281,870 priority patent/US20150017179A1/en
Priority to CY20161100837T priority patent/CY1117925T1/el
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US10/927,494 2003-08-29 2004-08-27 Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor Abandoned US20050202010A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
US10/927,494 US20050202010A1 (en) 2003-08-29 2004-08-27 Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
BRPI0413404-4A BRPI0413404A (pt) 2003-08-29 2004-08-30 composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif
MXPA06001828A MXPA06001828A (es) 2003-08-29 2004-08-30 Metodo para el tratamiento y bioensayo que involucra el factor de inhibicion de migracion de macrofagos ("mif"), como un factor de depresion del miocardio, derivado del corazon.
AU2004268017A AU2004268017B2 (en) 2003-08-29 2004-08-30 Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
EP04782427.1A EP1658037B1 (en) 2003-08-29 2004-08-30 Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor
CA2537928A CA2537928C (en) 2003-08-29 2004-08-30 Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor
HUE04782427A HUE029888T2 (en) 2003-08-29 2004-08-30 Treatment Method and Biological Test Using Macrophage Migration Factor (MIF) as a Factor for Heart Myocardial Depression
PL04782427T PL1658037T3 (pl) 2003-08-29 2004-08-30 Sposób leczenia i test biologiczny z udziałem czynnika hamującego migrację makrofagów (mif) jako czynnika depresji mięśnia sercowego pochodzenia sercowego
CN201110370579.7A CN102499984B (zh) 2003-08-29 2004-08-30 涉及作为心脏衍生的心肌抑制因子的巨噬细胞迁移抑制因子(mif)的治疗和生物测定方法
PT47824271T PT1658037T (pt) 2003-08-29 2004-08-30 Método de tratamento e bioensaio envolvendo o fator de inibição da migração de macrófagos (mif) como fator depressivo do miocárdio de origem cardíaca
ES04782427.1T ES2599032T3 (es) 2003-08-29 2004-08-30 Método de tratamiento y bioensayo que implica el factor de inhibición de la migración de macrófagos (MIF) como factor depresor del miocardio de origen cardiaco
EP16170803.7A EP3078386A3 (en) 2003-08-29 2004-08-30 Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor
DK04782427.1T DK1658037T3 (en) 2003-08-29 2004-08-30 Method and treatment of bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depression factor
CN2004800247776A CN1972713B (zh) 2003-08-29 2004-08-30 治疗或预防心脏功能障碍的药物组合物
JP2006524893A JP4891769B2 (ja) 2003-08-29 2004-08-30 マクロファージ遊走阻止因子（ｍｉｆ）を心臓由来心筋抑制因子として含む、処置方法およびバイオアッセイ
PCT/US2004/027945 WO2005020919A2 (en) 2003-08-29 2004-08-30 Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor
MX2011013436A MX340217B (es) 2003-08-29 2006-02-16 Metodo para el tratamietno y bioensayo que involucra el factor de inhibicion de migracion de macrofagos (mif), como un factor de depresion del miocardio, derivado del corazon.
US11/932,909 US8747843B2 (en) 2003-08-29 2007-10-31 Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
JP2010039451A JP5905659B2 (ja) 2003-08-29 2010-02-24 マクロファージ遊走阻止因子（ｍｉｆ）を心臓由来心筋抑制因子として含む、処置方法およびバイオアッセイ
JP2011133728A JP2011251966A (ja) 2003-08-29 2011-06-15 マクロファージ遊走阻止因子（ｍｉｆ）を心臓由来心筋抑制因子として含む、処置方法およびバイオアッセイ
US14/281,870 US20150017179A1 (en) 2003-08-29 2014-05-19 Method of Treatment and Bioassay Involving Macrophage Migration Inhibitory Factor (MIF) as Cardiac-Derived Myocardial Depressant Factor
CY20161100837T CY1117925T1 (el) 2003-08-29 2016-08-25 Μεθοδος αγωγης και βιοπροσδιορισμος που σχετιζεται με παραγοντα αναστολης της μεταναστευσης των μακροφαγων (mif) ως προερχομενο απο την καρδια μυοκαρδιακο κατασταλτικο παραγοντα

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US49865903P 2003-08-29 2003-08-29
US54705604P 2004-02-25 2004-02-25
US54705904P 2004-02-25 2004-02-25
US54705704P 2004-02-25 2004-02-25
US54705404P 2004-02-25 2004-02-25
US55644004P 2004-03-26 2004-03-26
US10/927,494 US20050202010A1 (en) 2003-08-29 2004-08-27 Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/932,909 Continuation US8747843B2 (en) 2003-08-29 2007-10-31 Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor

Publications (1)

Publication Number Publication Date
US20050202010A1 true US20050202010A1 (en) 2005-09-15

Family

ID=34280266

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/927,494 Abandoned US20050202010A1 (en) 2003-08-29 2004-08-27 Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
US11/932,909 Active 2027-03-21 US8747843B2 (en) 2003-08-29 2007-10-31 Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
US14/281,870 Abandoned US20150017179A1 (en) 2003-08-29 2014-05-19 Method of Treatment and Bioassay Involving Macrophage Migration Inhibitory Factor (MIF) as Cardiac-Derived Myocardial Depressant Factor

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/932,909 Active 2027-03-21 US8747843B2 (en) 2003-08-29 2007-10-31 Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
US14/281,870 Abandoned US20150017179A1 (en) 2003-08-29 2014-05-19 Method of Treatment and Bioassay Involving Macrophage Migration Inhibitory Factor (MIF) as Cardiac-Derived Myocardial Depressant Factor

Country Status (15)

Country Link
US (3) US20050202010A1 (pt)
EP (2) EP1658037B1 (pt)
JP (3) JP4891769B2 (pt)
CN (2) CN1972713B (pt)
AU (1) AU2004268017B2 (pt)
BR (1) BRPI0413404A (pt)
CA (1) CA2537928C (pt)
CY (1) CY1117925T1 (pt)
DK (1) DK1658037T3 (pt)
ES (1) ES2599032T3 (pt)
HU (1) HUE029888T2 (pt)
MX (2) MXPA06001828A (pt)
PL (1) PL1658037T3 (pt)
PT (1) PT1658037T (pt)
WO (1) WO2005020919A2 (pt)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080241145A1 (en) * 2004-12-08 2008-10-02 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
WO2009117706A3 (en) * 2008-03-20 2010-01-21 Carolus Therapeutics, Inc. Methods of treatment using anti-mif antibodies
WO2010065491A2 (en) * 2008-12-01 2010-06-10 Carolus Therapeutics, Inc. Methods of treating inflammatory disorders
US20100183598A1 (en) * 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders
US20110070184A1 (en) * 2008-03-24 2011-03-24 Carolus Therpeutics, Inc. Methods and compositions for treating atherosclerosis and related condidtions
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050202010A1 (en) 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
CA2557166C (en) * 2004-03-26 2015-06-30 Cytokine Pharmasciences, Inc. Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
WO2006116688A2 (en) * 2005-04-26 2006-11-02 Yale University Mif agonists and antagonists and therapeutic uses thereof
EP2742348A4 (en) * 2011-08-12 2015-07-22 Alfred Health METHOD FOR THE DIAGNOSIS, FORECAST OR TREATMENT OF ACUTE CORONARY SYNDROME (ACS) BY MEASUREMENT OF THE PLASMA CONCENTRATION OF THE MACROPHAGE MIGRATION INHIBITION FACTOR (MIF)
JP2014530360A (ja) 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 診断マーカーとしてのｏｘＭＩＦ
US20150309012A1 (en) * 2012-12-07 2015-10-29 Baxter International Inc. Anti-mif antibody cell migration assay
CN105087610A (zh) * 2015-09-11 2015-11-25 中国科学院海洋研究所 文蛤巨噬细胞迁移抑制因子基因及其编码蛋白和应用
JP2018007029A (ja) * 2016-07-01 2018-01-11 株式会社村田製作所 バイアス回路
WO2022235865A1 (en) * 2021-05-06 2022-11-10 Abbott Molecular Inc. Compositions and methods for simple sample extraction
CN114288387A (zh) * 2022-02-17 2022-04-08 重庆医科大学 Humanin衍生物HNG在制备治疗心衰药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030615A (en) 1993-05-17 2000-02-29 The Picower Institute For Medical Research Combination method for treating diseases caused by cytokine-mediated toxicity
US6420188B1 (en) 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
ATE238061T1 (de) * 1997-11-05 2003-05-15 Univ Southern California Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten
CA2389229A1 (en) 1999-10-29 2001-05-10 The Picower Institute For Medical Research Compounds having mif antagonist activity
US6268151B1 (en) 2000-01-20 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of macrophage migration inhibitory factor expression
WO2001064749A2 (en) * 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
CA2455915C (en) * 2001-03-29 2013-05-14 Cytokine Pharmasciences, Inc. Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
EP1411930B1 (en) * 2001-06-08 2013-01-16 Cytokine Pharmasciences, Inc. Isoxazoline compounds having mif antagonist activity
US20050202010A1 (en) 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080241145A1 (en) * 2004-12-08 2008-10-02 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
US8420786B2 (en) * 2004-12-08 2013-04-16 Immunomedics, Inc. Bispecific antibody targeting a complement factor or complement regulatory protein
WO2009117706A3 (en) * 2008-03-20 2010-01-21 Carolus Therapeutics, Inc. Methods of treatment using anti-mif antibodies
EP2254597A2 (en) * 2008-03-20 2010-12-01 Carolus Therapeutics, Inc. Methods of treatment using anti-mif antibodies
US20110044988A1 (en) * 2008-03-20 2011-02-24 Carolus Therpeutics, Inc. Methods of treatment using anti-mif antibodies
EP2254597A4 (en) * 2008-03-20 2012-04-18 Carolus Therapeutics Inc TREATMENT PROCEDURE WITH ANTI-MIF ANTIBODIES
US20110070184A1 (en) * 2008-03-24 2011-03-24 Carolus Therpeutics, Inc. Methods and compositions for treating atherosclerosis and related condidtions
US20100183598A1 (en) * 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders
WO2010065491A2 (en) * 2008-12-01 2010-06-10 Carolus Therapeutics, Inc. Methods of treating inflammatory disorders
WO2010065491A3 (en) * 2008-12-01 2010-09-30 Carolus Therapeutics, Inc. Methods of treating inflammatory disorders
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)

Also Published As

Publication number Publication date
AU2004268017A2 (en) 2005-03-10
US20080260723A1 (en) 2008-10-23
CY1117925T1 (el) 2017-05-17
MX340217B (es) 2016-06-30
BRPI0413404A (pt) 2006-10-17
AU2004268017B2 (en) 2011-03-17
US8747843B2 (en) 2014-06-10
US20150017179A1 (en) 2015-01-15
AU2004268017A1 (en) 2005-03-10
CN1972713B (zh) 2012-02-29
JP2007504158A (ja) 2007-03-01
CN102499984A (zh) 2012-06-20
CA2537928C (en) 2015-05-05
PT1658037T (pt) 2016-08-30
CA2537928A1 (en) 2005-03-10
WO2005020919A3 (en) 2006-11-30
EP3078386A3 (en) 2017-01-11
DK1658037T3 (en) 2016-08-29
MXPA06001828A (es) 2007-05-23
JP4891769B2 (ja) 2012-03-07
EP1658037B1 (en) 2016-05-25
ES2599032T3 (es) 2017-01-31
CN102499984B (zh) 2015-02-18
JP2011251966A (ja) 2011-12-15
CN1972713A (zh) 2007-05-30
EP3078386A2 (en) 2016-10-12
EP1658037A2 (en) 2006-05-24
JP2010159267A (ja) 2010-07-22
EP1658037A4 (en) 2008-09-10
WO2005020919A2 (en) 2005-03-10
PL1658037T3 (pl) 2017-08-31
HUE029888T2 (en) 2017-04-28
JP5905659B2 (ja) 2016-04-20

Similar Documents

Publication Publication Date Title
US8747843B2 (en) Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
JP6066474B2 (ja) 中和プロラクチン受容体抗体およびそれらの治療的使用
EP2170366B1 (en) Use of tlr-2 antagonists for treatment of reperfusion injury and tissue damage
EP2902495A1 (en) Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
US8765126B2 (en) Methods of treating complications and disorders associated with G-CSF administration
KR20180135928A (ko) 간 질환을 치료하거나 예방하는 방법
JP2024008945A (ja) 膵島細胞の増殖を促進する方法
KR20220152554A (ko) 코로나바이러스-유도된 급성 호흡 곤란 증후군의 치료 및/또는 예방을 위해 masp-2를 억제하는 방법
EP2773668B1 (en) Pulmonary hypertension
US20090004182A1 (en) Methods to Treat or Prevent Viral-Associated Lymphoproliferative Disorders
US20220267428A1 (en) BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS
JP2005516907A (ja) 霊長類ｉｆｎ−ガンマ結合分子の使用
TWI834025B (zh) 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法
US10925951B2 (en) Vaccination against diabetes, obesity and complications thereof
WO2024018440A1 (en) Neutralization of acyl-coa binding protein for the treatment of cardiac dysfunction
JP2024507986A (ja) 抗体関連型移植拒絶反応の治療に使用するための抗ｃｄ３８抗体
JP2024509702A (ja) 急性ｃｏｖｉｄ－１９および急性後ｃｏｖｉｄ－１９を発症するリスクを評価するためのバイオマーカー
JP2024503432A (ja) 抗ｃｄ３８抗体及び抗ｃｄ３８抗体の使用
JP2023526091A (ja) がんの予防または治療用薬学的組成物
CN117561078A (zh) 用于评价发展急性covid-19和急性后covid-19的风险的生物标志物
Bilinski Evaluation of UNK Cell Capacity to Initiate Pregnancy-associated Spiral Artery Remodelling

Legal Events

Date Code Title Description
AS Assignment

Owner name: CYTOKINE PHARMASCIENCES, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GIROIR, BRETT P.;WILLIS, MONTE S.;DE LA CRUZ JR., VIDAL F;AND OTHERS;REEL/FRAME:016654/0228;SIGNING DATES FROM 20050419 TO 20050527

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GIROIR, BRETT P.;WILLIS, MONTE S.;DE LA CRUZ JR., VIDAL F;AND OTHERS;REEL/FRAME:016654/0228;SIGNING DATES FROM 20050419 TO 20050527

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF TEXAS SW MEDICAL CENTER AT DALLAS;REEL/FRAME:021700/0005

Effective date: 20040922